View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 23, 2021updated 11 Jul 2022 2:14pm

Mereo, UAB report positive data from Phase Ib/II Covid-19 oral drug trial 

In the trial, 62.5% in the alvelestat group had a two-point decline in the WHO Disease Severity score by day five.

Mereo BioPharma and the University of Alabama at Birmingham (UAB) in the US have reported positive results from the Phase Ib/II COSTA clinical trial of a new oral drug, alvelestat, in hospitalised Covid-19 patients with respiratory disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Alvelestat is an active inhibitor of Neutrophil Elastase (NE).

The randomised, placebo-controlled, single-site, double-blind, investigator-led trial assessed the safety and tolerability of alvelestat plus standard of care (SOC) in adult subjects aged 18 years and above with Covid-19 respiratory disease.

Subjects were given alvelestat or placebo twice a day for five days with an option to extend the treatment to ten days as per the investigator’s choice.

The primary goal was safety and tolerability to day 60, with mortality analysis at day 90.

Clinical outcomes to day 60 were the trial’s secondary goals.

Findings showed that alvelestat was safe and well-tolerated in Covid-19-infected individuals.

No safety signals were reported in lab safety monitoring which is in line with the already reported safety profile of the oral drug.

In the trial, four subjects who received alvelestat had treatment-emergent headaches which were more frequent than placebo arm with one case observed.

This event was concluded to be not linked to the trial drug with no difference in frequency of other adverse events between alvelestat and placebo groups noted till day 60.

Alvelestat plus SOC offered a quicker time to improvement in WHO Disease Severity score of >=2 in the initial five to seven days versus placebo plus SOC.

By day five, nearly 62.5% of the subjects in the alvelestat arm exhibited a two-point decline in the WHO Disease Severity score versus 28.5% in the placebo group.

Furthermore, on day seven, the alvelestat arm’s improvement score climbed to 87.5% as against 57% in subjects who received placebo.

UAB Pulmonary, Allergy and Critical Care Medicine associate professor Dr Mike Wells said: “The early results with alvelestat suggest a potential for clinical benefit over and above the standard of care including dexamethasone and remdesivir.

“This is exciting given the ease of administration of a well-tolerated oral therapy in this acutely ill population. These findings provide strong data and set the stage for future studies with relevant clinical end-points.”

In December 2018, Mereo BioPharma announced plans to merge business with OncoMed Pharmaceuticals.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena